Peter S Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9148252/publications.pdf

Version: 2024-02-01

1307594 1474206 9 852 7 9 citations g-index h-index papers 9 9 9 1748 citing authors all docs docs citations times ranked

#	Article	IF	Citations
1	Features of responding T cells in cancer and chronic infection. Current Opinion in Immunology, 2010, 22, 223-230.	5.5	263
2	Serine racemase: Activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2105-2110.	7.1	200
3	IL-15 superagonist/IL-15Rî±Sushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget, 2016, 7, 16130-16145.	1.8	138
4	Altered Patterns of Cellular Gene Expression in Dermal Microvascular Endothelial Cells Infected with Kaposi's Sarcoma-Associated Herpesvirus. Journal of Virology, 2002, 76, 3395-3420.	3.4	106
5	Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs. Journal of Clinical Investigation, 2008, 118, 1700-1711.	8.2	74
6	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunology Research, 2016, 4, 755-765.	3.4	36
7	Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy. Journal of Immunology, 2014, 192, 2622-2633.	0.8	25
8	Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy. Oncolmmunology, 2014, 3, e29351.	4.6	5
9	Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy. Oncolmmunology, 2015, 4, e1009303.	4.6	5